John Libbey Eurotext

European Journal of Dermatology

A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs Volume 27, issue 3, May-June 2017

Figures

  • Figure 1
  • Figure 2
  • Figure 3

Tables

Authors
Pietro Quaglino on behalf of the EORTC Cutaneous T-Cell Lymphoma Task Force 18
1 Department of Dermatology,
APHP - Hopital Saint-Louis-Paris Cedex 10,
France
2 European Organisation for Research and Treatment of Cancer,
Headquarters,
Brussels, Belgium
3 St Johns institute of dermatology and Department of Clinical Oncology,
Guys Hospital,
London,
UK
4 Department of Dermatology-University Hospital of Bordeaux,
INSERM U 1053 Bordeaux,
France
5 Division of Dermatology and Dermato-Oncology,
Department of Dermatology,
Medical University of Vienna,
Vienna,
Austria
6 Medical Oncology Department,
National Cancer Institute,
Cairo University,
Cairo,
Egypt
7 Unit of Dermatology,
Institut du Cancer-HCL,
Centre de recherché ne Cancérologie de Lyon,
Université Claude Bernard Lyon 1,
Lyon,
France
8 Department of Dermatology,
Hospital Universitari de Bellvitge. IDIBELL. Barcelona University. Barcelona,
Spain
9 Department of Clinical Oncology,
Christie Hospital ,
University of Manchester,
UK
10 Helsinki University Central Hospital,
Skin and Allergy Hospital,
Helsinki,
Finland
11 Department of Dermatology,
Hopital Nord,
Amiens,
France
12 Department of Clinical Haematology,
Nottingham University Hospitals NHS Trust (City Campus),
UK
13 Department of Oncology- Beatson West of Scotland Cancer Centre - Gartnavel General Hospital, Glasgow, UK
14 Department Dermatology Leiden University Medical Centre Leiden,
the Netherlands
15 Department of Dermatology,
Johannes Wesling Klinikum,
Minden,
Germany
16 Hospital 12 de Octubre,
Medical School,
Universidad Complutense,
Institute i+12,
Madrid,
Spain
17 Department Dermatology,
University Hospital Birmingham,
Birmingham,
UK
18 Dermatologic Clinic,
Department of Medical Sciences,
University of Turin,
Italy
* Reprints
  • Key words: cutaneous T-cell lymphoma, maintenance treatment, randomized trial, lenalinomide, anti-angiogenic
  • DOI : 10.1684/ejd.2017.3008
  • Page(s) : 286-94
  • Published in: 2017

Background

EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs).